Every Form 4 that Ardent Health, Inc. (ARDT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ARDT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARDT filings page.
Ardent Health, Inc. Chief Financial Officer Alfred Lumsdaine had 3,389 shares of common stock withheld for taxes upon vesting of restricted stock units on September 25, 2026, in accordance with Rule 16b-3. His direct holdings following the transaction were 325,794 shares.
Ardent Health, Inc. (ARDT) reported that Stephen C. Petrovich, EVP, GC and Secretary, had 788 shares withheld for taxes upon vesting of restricted stock units on September 25, 2026. The reported price was the $10.54 closing price per share. His direct common-stock holdings following the transaction were 773,919 shares. Separate indirect holdings are listed in the Stephen C. Petrovich GST-2016 Exempt Family Trust and Emilie K. Petrovich GST-2016 Exempt Family Trust; Petrovich disclaims beneficial ownership except to the extent of any pecuniary interests.
Ardent Health, Inc.'s SVP & Chief Accounting Officer, David Raynor Byers, had 524 common shares withheld for payment of taxes upon vesting of restricted stock units on September 25, 2026, in accordance with Rule 16b-3. The reported price was $10.54 per share, equal to the issuer's closing price that day. Byers directly held 129,921 shares after the transaction.
Caspers Dave reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. reported that CEO and President Dave Caspers received an equity grant of 103,653 shares of Common Stock in the form of restricted stock units. These units vest in three substantially equal installments on each anniversary of July 1, 2026, as long as he remains with the company through each vesting date.
Following this award, Caspers directly holds 174,930 shares of Ardent Health common stock. The grant is compensation-related and was not an open-market purchase, as it carried a grant price of $0.00 per share.
Ardent Health, Inc. director Robert DeMichiei reported an open-market purchase of Common Stock. He bought 11,260 shares at a weighted average price of $8.73 per share, increasing his direct holdings to 35,564 shares. The trade was executed through multiple transactions on June 5, 2026 at prices between $8.60 and $8.78.
Ardent Health, Inc. Chief Financial Officer Alfred Lumsdaine made an open-market purchase of 10,000 shares of Common Stock at $8.81 per share. After this transaction, he directly owns 329,183 shares, increasing his personal stake in the company.
Ardent Health, Inc. director Peter J. Bulgarelli reported receiving a grant of 14,231 shares of common stock in the form of restricted stock units at no cash exercise price. Following this award, he holds 14,231 shares directly. The units vest in full on the first anniversary of April 1, 2026, conditioned on his continued service with the company through that vesting date.
Havdala Ellen reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director Ellen Havdala reported receiving a grant of 14,231 shares of common stock in the form of restricted stock units. These units will vest in full on the first anniversary of April 1, 2026, as long as she continues serving the company through that date. After this grant, she holds 115,367 shares of common stock directly.
Sotir Mark R reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director and Chair of the Board Mark R. Sotir received an award of 14,231 shares of Common Stock in the form of restricted stock units at no purchase price. These units vest in full on the first anniversary of April 1, 2026, contingent on his continued service with the company. Following this grant, he holds 38,709 shares directly.
Sen Rahul reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director Rahul Sen reported an award of 14,231 shares of Common Stock in the form of restricted stock units. These units were granted at no cash cost and will vest in full on the first anniversary of April 1, 2026, contingent on his continued service. Following this compensation-related grant, Sen’s directly owned and awarded position totals 38,709 shares.
Webb Robert Thomas reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director Robert Thomas Webb reported an equity award of 14,231 shares of Common Stock, received as a grant on April 1, 2026 at no purchase price. These represent restricted stock units that vest in full on the first anniversary of April 1, 2026, subject to his continued service. Following this award, Webb directly holds a total of 78,215 shares of Common Stock.
Robinson Edmondo reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director Edmondo Robinson received a grant of 14,231 shares of Common Stock in the form of restricted stock units. These units vest in full on the first anniversary of April 1, 2026, if he remains in service with the company through that date. Following this award, he directly holds 58,215 shares of Common Stock.
Ardent Health, Inc. reported that director Robert DeMichiei received a grant of 14,231 restricted stock units representing its common stock. The award was granted at no cash cost and vests in full on the first anniversary of April 1, 2026, contingent on his continued service. Following this equity grant, he directly holds 24,304 shares of Ardent Health common stock. Restricted stock units are a form of share-based compensation that convert into shares when vesting conditions are met, aligning the director’s interests with long-term company performance.
GOODYEAR WILLIAM M reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director William M. Goodyear received a grant of 14,231 shares of common stock in the form of restricted stock units at no cost. These units vest in full on the first anniversary of April 1, 2026, if he remains in service with the company. Following this award, he directly holds 115,367 shares of Ardent Health common stock.
Campion Suzanne reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director Suzanne Campion reported receiving a grant of 14,231 shares of common stock in the form of restricted stock units. These units vest in full on the first anniversary of April 1, 2026, if she continues serving with the company through that date. After this award, she directly holds 58,215 shares of common stock, reflecting a routine equity-based compensation grant rather than an open-market purchase.
BYNOE PETER C B reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director Peter C. B. Bynoe reported an equity award of 14,231 shares of Common Stock, received as a grant at no cash cost per share. These are restricted stock units that vest in full on the first anniversary of April 1, 2026, subject to his continued service. Following this award, he holds 115,367 shares directly.
Ardent Health, Inc. Chief Operating Officer Dave Caspers received an equity award of 35,673 shares of Common Stock on April 1, 2026 as a grant or award. The award represents restricted stock units that vest in three substantially equal installments on each anniversary of April 1, 2026, subject to his continued service with the company.
On the same date, 2,684 shares were withheld at $8.67 per share to cover tax obligations in accordance with Rule 16b-3, a routine tax-withholding disposition rather than an open-market sale. After these transactions, Caspers directly owned 71,277 shares of Common Stock.
Ardent Health EVP, GC and Secretary Stephen C. Petrovich received a grant of 24,904 shares of common stock as restricted stock units that vest in three substantially equal installments on each anniversary of April 1, 2026, subject to continued service. To cover tax obligations on RSU vesting, 1,425 shares on March 31, 2026 at $8.56 and 1,808 shares on April 1, 2026 at $8.67 were withheld rather than sold on the open market. Following these compensation-related transactions, he holds 774,707 shares directly, and 186,225 shares are reported as indirectly held in family GST‑2016 Exempt Family Trusts for which he disclaims beneficial ownership except for any pecuniary interest.
Ardent Health, Inc. senior vice president and chief accounting officer David Raynor reported routine equity compensation activity in the company’s stock. On April 1, 2026 he received a grant of 11,538 shares of common stock at no cost, tied to restricted stock units that vest in three substantially equal installments on each anniversary of April 1, 2026, subject to his continued service. To cover taxes owed on RSU vesting, 924 shares were withheld on April 1, 2026 at $8.67 per share and 819 shares were withheld on March 31, 2026 at $8.56 per share, consistent with Rule 16b-3 treatment rather than open‑market sales. Following these transactions, Raynor directly owned 130,445 shares of Ardent Health common stock.
Ardent Health, Inc. Chief Financial Officer Alfred Lumsdaine reported routine equity compensation activity in common stock. On April 1, 2026, he received a grant of 53,846 shares, representing restricted stock units that vest in three equal installments from April 1, 2026. To cover taxes on RSU vesting, the company withheld 2,510 shares on March 31, 2026 at $8.56 per share and 4,381 shares on April 1, 2026 at $8.67 per share under Rule 16b-3. Following these transactions, he directly holds 319,183 common shares.
Ardent Health, Inc. President and CEO Martin Bonick reported compensation-related stock activity involving restricted stock units and associated tax withholding.
On April 1, 2026, he received 134,615 shares of common stock as a grant or award. These restricted stock units vest in three substantially equal installments on each anniversary of April 1, 2026, subject to his continued service with the company.
To cover tax obligations upon vesting of restricted stock units under Rule 16b-3, 10,952 shares were withheld at a reference price of $8.67 per share on April 1, 2026 and 8,026 shares were withheld at $8.56 per share on March 31, 2026. Following these transactions, Bonick directly owned 1,437,937 shares of Ardent Health common stock.
Petrovich Stephen C. reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. executive vice president, general counsel and secretary Stephen C. Petrovich was granted 34,733 shares of common stock on March 11, 2026 as a performance-based award. The shares were earned under performance-vesting restricted stock units granted on July 18, 2024 and will vest on December 31, 2026, contingent on continued service.
Following this award, Petrovich directly owns 753,036 shares of Ardent Health common stock. The filing also reports additional indirect holdings of common stock through 2016 exempt family trusts benefiting his children, for which he disclaims beneficial ownership except for any pecuniary interest.
Ardent Health, Inc. Chief Financial Officer Alfred Lumsdaine reported an equity compensation award on Common Stock. He acquired 61,081 shares on March 11, 2026 at a stated price of $0.00 per share, reflecting a grant or award rather than an open-market purchase.
According to the footnote, these shares were earned based on 2024 and 2025 performance under performance-vesting restricted stock units granted on July 18, 2024, and will vest on December 31, 2026 if he remains in service through that date. Following this award, he directly holds 272,228 Common Stock shares.
Chernin Ethan reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. President of Health Services Ethan Chernin reported receiving a grant of 32,408 shares of Common Stock as compensation, with no purchase price paid per share.
These shares were earned based on 2024 and 2025 performance under performance-vesting restricted stock units awarded on July 18, 2024. They will vest on December 31, 2026, contingent on continued service through that date. After this award, Chernin directly holds 68,396 shares of Ardent Health common stock.
Bonick Martin reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. President and CEO Martin Bonick received a grant of 195,316 shares of common stock at no cost as part of his equity compensation. These shares were earned based on 2024 and 2025 performance under performance-vesting restricted stock units awarded on July 18, 2024.
The granted shares will vest on December 31, 2026, contingent on his continued service through that date, meaning he does not fully own them until then. Following this award, Bonick directly holds 1,322,300 shares of Ardent Health common stock.
Byers David Raynor reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. reported that SVP & Chief Accounting Officer David Raynor Byers received a grant of 8,859 shares of common stock as a compensation award. These shares were earned based on 2024 and 2025 performance under performance-vesting restricted stock units and will vest on December 31, 2026, contingent on continued service through that date. Following this award, he directly holds 120,650 shares of common stock.